2[2]John T,Bouchard CS.Usefulness of preserved human amniotic membrane transplantation in anterior segment ocular diseases[J].Invest Ophthalmol Vis Sci 1999;40∶s327.
3[3]Barequet IS,Denton P,Osterhout GJ,et al.Predictive value of inhibitory quotient in therapy of experimental keratitis[J].Invest Ophthalmol Vis Sci1999;40∶s327.
4[4]Gabric N,Dekaris I,Mravicic I,et al.Amniotic membrane transplantation in surgical reconstruction of the ocular surface[J].Invest Ophthalmol Vis Sci1999;40∶s327.
5[5]Lee S,Tseng SCG.Amniotic membrane transplantation for persistent epithelial defects with ulceration[J].Am J Ophthalmol 1997;123∶303-312.
6[6]Zagorski ZF,Rakowska E,Kardaszewska A.Amniotic membrane transplantation in the treatment of severe corneal disorders[J].Invest Ophthalmol Vis Sci 1999;40∶s327.
7[7]Na BK,Hwang JH,Shin EJ,et al.Analysis of human amniotic membrane components as proteinase inhibitors for development of therapeutic agent of recalcitrant keratitis[J].Invest Ophthalmol Vis Sci 1998;39∶S90.
8[8]Bültmann S,You L,Spandau V,et al.Amniotic membrane down-regulates chemokine expression in human keratocytes[J].Invest Ophthalmol Vis Sci 1999;40∶s578.
9[9]Sato H,Shimazaki J,Shimazaki N,et al.Role of growth factors for ocular surface reconstruction after amniotic membrane transplantation[J].Invest Ophthalmol Vis Sci 1998;39∶s428.
10[10]Monteiro ECL,Schellini SA,Marques MEA,et al.Treatment of experimental corneal ulcer with homologous amniotic membrane in rabbits[J].Invest Ophthalmol Vis Sci 1999;40∶s328.
